Serum uric acid and risk of ischemic stroke: The ARIC Study

Atherosclerosis

Volumn 187, Issue 2, 2006, Pages 401-407

  Hozawa, Atsushi ^a,b   Folsom, Aaron R ^a   Ibrahim, Hassan ^c   Javier Nieto, F ^d   Rosamond, Wayne D ^e   Shahar, Eyal ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e IL   (United States)

Author keywords

Diuretics; Prospective studies; Stroke; Uric acid

Indexed keywords

DIURETIC AGENT; URIC ACID;

ADULT; AGE DETERMINATION; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RACE; RISK FACTOR; SEX DETERMINATION; SOCIOECONOMICS; STROKE; URIC ACID BLOOD LEVEL;

BIOLOGICAL MARKERS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PREVALENCE; RISK FACTORS; SEX DISTRIBUTION; STROKE; URIC ACID;

EID: 33745491875     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2005.09.020     Document Type: Article

References (46)

1. Johnson R.J., Kang D.H., Feig D., et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?. Hypertension 41 (2003) 1183-1190
2. Rich M.W. Uric acid: is it a risk factor for cardiovascular disease?. Am J Cardiol 85 (2000) 1018-1021
3. Brand F.N., McGee D.L., Kannel W.B., Stokes III J., and Castelli W.P. Hyperuricemia as a risk factor of coronary heart disease: the Framingham study. Am J Epidemiol 121 (1985) 11-18
4. Tomita M., Mizuno S., Yamanaka H., et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol 10 (2000) 403-409
5. Mazza A., Pessina A.C., Pavei A., et al. Predictors of stroke mortality in elderly people from the general population. The CArdiovascular STudy in the ELderly. Eur J Epidemiol 17 (2001) 1097-1104
6. Wang J.G., Staessen J.A., Fagard R.H., et al. Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension 37 (2001) 1069-1074
7. Longo-Mbenza B., Luila E.L., Mbete P., and Vita E.K. Is hyperuricemia a risk factor of stroke and coronary heart disease among Africans?. Int J Cardiol 71 (1999) 17-22
8. Lehto S., Niskanen L., Ronnemaa T., and Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke 29 (1998) 635-639
9. Goldberg R.J., Burchfiel C.M., Benfante R., et al. Lifestyle and biologic factors associated with atherosclerotic disease in middle-aged men. 20-Year findings from the Honolulu Heart Program. Arch Intern Med 155 (1995) 686-694
10. Franse L.V., Pahor M., Di Bari M., et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 18 (2000) 1149-1154
11. Niskanen L.K., Laaksonen D.E., Nyyssonen K., et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 164 (2004) 1546-1551
12. Moriarity J.T., Folsom A.R., Iribarren C., Nieto F.J., and Rosamond W.D. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol 10 (2000) 136-143
13. Yusuf S., and Bosch J. Urate levels as a predictor of cardiac deaths: causal relation or mere association?. Eur Heart J 23 (2002) 760-761
14. Culleton B.F., Larson M.G., Kannel W.B., and Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 131 (1999) 7-13
15. Nieto F.J., Iribarren C., Gross M.D., Comstock G.W., and Cutler R.G. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis?. Atherosclerosis 148 (2000) 131-139
16. Reyes A.J. Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther 17 (2003) 397-414
17. Reyes A.J., and Leary W.P. The increase in serum uric acid induced by diuretics could be beneficial to cardiovascular prognosis in hypertension: a hypothesis. J Hypertens 21 (2003) 1775-1777
18. Sakata K., Hashimoto T., Ueshima H., Okayama A., and NIPPON DATA 80 Research Group. Absence of an association between serum uric acid and mortality from cardiovascular disease: NIPPON DATA 80, 1980-1994. National Integrated Projects for Prospective Observation of Non-communicable Diseases and its Trend in the Aged. Eur J Epidemiol 17 (2001) 461-468
19. De Leeuw P.W., Thijs L., Birkenhager W.H., et al., Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial. J Am Soc Nephrol 13 (2002) 2213-2222
20. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol 129 (1989) 687-702
21. Eckfeldt J.H., Chambless L.E., and Shen Y.L. Short-term, within-person variability in clinical chemistry test results. Experience from the Atherosclerosis Risk in Communities Study. Arch Pathol Lab Med 118 (1994) 496-500
22. 2+ precipitation. Clin Chem 28 (1982) 1574
23. National Heart, Lung, and Blood Institute. Atherosclerosis Risk in Communities (ARIC) Study. Operations manual no. 9: hemostasis determinations, version 1.0. Chapel Hill, NC: ARIC Coordinating Center, School of Public Health, University of North Carolina; 1987.
24. Wu K.K., Papp A.C., Patsch W., et al. ARIC hemostasis study. II. Organizational plan and feasibility study. Thromb Haemost 64 (1990) 521-525
25. Sharrett A.R. The Atherosclerosis Risk in Communities (ARIC) Study: introduction and objectives of the hemostasis component. Ann Epidemiol 2 (1992) 467-469
26. National Heart, Lung, and Blood Institute. Atherosclerosis Risk in Communities (ARIC) Study. Operations manual no. 10: clinical chemistry determinations, version 1.0. Chapel Hill, NC: ARIC Coordinating Center, School of Public Health, University of North Carolina; 1987.
27. Chambless L.E., McMahon R.P., Brown S.A., et al. Short-term intraindividual variability in lipoprotein measurements: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 136 (1992) 1069-1081
28. Chambless L.E., McMahon R., Wu K., et al. Short-term intraindividual variability in hemostasis factors: the ARIC Study. Ann Epidemiol 2 (1992) 723-733
29. National Heart, Lung, and Blood Institute. Atherosclerosis Risk in Communities (ARIC) Study. Operations manual no. 2: cohort component procedures, version 1.0. Chapel Hill, NC: ARIC Coordinating Center, School of Public Health, University of North Carolina; 1987.
30. Fuchs F.D., Chambless L.E., Whelton P.K., Nieto F.J., and Heiss G. Alcohol consumption and the incidence of hypertension: the Atherosclerosis Risk in Communities Study. Hypertension 37 (2001) 1242-1250
31. National Heart, Lung, and Blood Institute. Atherosclerosis Risk in Communities (ARIC) Study. Operations manual no. 11: sitting blood pressure, version 1.0. Chapel Hill, NC: ARIC Coordinating Center, School of Public Health, University of North Carolina; 1987.
32. National Heart, Lung, and Blood Institute. Atherosclerosis Risk in Communities Study (ARIC). Operations manual no. 5: electrocardiography, version 1.0. Chapel Hill, NC: ARIC Coordinating Center, School of Public Health, University of North Carolina; 1987.
33. Crow R.S., Prineas R.J., Rautaharju P., Hannan P., and Liebson P.R. Relation between electrocardiography and echocardiography for left ventricular mass in mild systolic hypertension (results from Treatment of Mild Hypertension Study). Am J Cardiol 75 (1995) 1233-1238
34. Pignoli P., Tremoli E., Poli A., Oreste P., and Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 74 (1986) 1399-1406
35. National Heart, Lung, and Blood Institute. Atherosclerosis Risk in Communities (ARIC) Study. Operations manual no. 6A: ultrasound assessment-part A, ultrasound scanning, version 1.0. Chapel Hill, NC: ARIC Coordinating Center, School of Public Health, University of North Carolina; 1987.
36. Bond M.G., Barnes R.W., Riley W.A., et al., the ARIC Study Group. High-resolution B-mode ultrasound scanning methods in the Atherosclerosis Risk in Communities Study (ARIC). J Neuroimaging 1 (1991) 68-73
37. National Heart, Lung, and Blood Institute. Atherosclerosis Risk in Communities (ARIC) Study. Operations manual no. 6B: ultrasound assessment-part A, ultrasound reading, version 1.0. Chapel Hill, NC: ARIC Coordinating Center, School of Public Health, University of North Carolina; 1987.
38. Chambless L.E., Heiss G., Folsom A.R., et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 146 (1997) 483-894
39. Chambless L.E., Heiss G., Shahar E., Earp M.J., and Toole J. Prediction of ischemic stroke risk in the Atherosclerosis Risk in Communities Study. Am J Epidemiol 160 (2004) 259-269
40. National Heart, Lung, and Blood Institute. Atherosclerosis Risk in Communities (ARIC) Study. Operations manual no. 3: surveillance component procedures, version 1.0. Chapel Hill, NC: ARIC Coordinating Center, School of Public Health, University of North Carolina; 1987.
41. Rosamond W.D., Folsom A.R., Chambless L.E., et al. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke 30 (1999) 736-743
42. The National Survey of Stroke. National Institute of Neurological and Communicative Disorders and Stroke. Stroke 1981;12(2 Pt 2 Suppl. 1):I1-91.
43. Shahar E., Chambless L.E., Rosamond W.D., et al. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke 34 (2003) 623-633
44. Klein B.E., Klein R., and Lee K.E. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care 25 (2002) 1790-1794
45. Psaty B.M., Lumley T., Furberg C.D., et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 289 (2003) 2534-2544
46. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002) 2981-2997